Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.

Saved in:
Bibliographic Details
Title: Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
Authors: Nowak RJ; Department of Neurology, Yale University School of Medicine, New Haven, CT richard.nowak@yale.edu., Coffey CS; Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA., Goldstein JM; Department of Neurology, Hospital for Special Surgery, New York, NY., Dimachkie MM; Department of Neurology, Kansas University School of Medicine, Kansas City, KS., Benatar M; Department of Neurology, University of Miami Miller School of Medicine, Miami, FL., Kissel JT; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH., Wolfe GI; Department of Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY., Burns TM; Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA., Freimer ML; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH., Nations S; Department of Neurology, University of Texas Southwestern Medical School, Dallas, TX., Granit V; Department of Neurology, Albert Einstein College of Medicine, Bronx, NY.; Department of Neurology, University of Miami Miller School of Medicine, Miami, FL., Smith AG; Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT., Richman DP; Department of Neurology, University of California Davis School of Medicine, Sacramento, CA., Ciafaloni E; Department of Neurology, University of Rochester School of Medicine & Dentistry, Rochester, NY., Al-Lozi MT; Department of Neurology, Washington University School of Medicine, St. Louis, MO., Sams LA; Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, OH., Quan D; Department of Neurology, University of Colorado School of Medicine, Aurora, CO., Ubogu E; Department of Neurology, The University of Alabama at Birmingham School of Medicine, Birmingham, AL., Pearson B; Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA., Sharma A; Department of Neurology, Yale University School of Medicine, New Haven, CT.; Department of Neurology, University of Iowa, Iowa City, IA., Yankey JW; Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA., Uribe L; Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA., Shy M; Department of Neurology, University of Iowa, Carver College of Medicine, Iowa City, IA., Amato AA; Department of Neurology, Brigham and Women's Hospital, Boston, MA., Conwit R; Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Rockville, MD., O'Connor KC; Department of Neurology, Yale University School of Medicine, New Haven, CT., Hafler DA; Department of Neurology, Yale University School of Medicine, New Haven, CT., Cudkowicz ME; Department of Neurology, Massachusetts General Hospital, Boston, MA., Barohn RJ; Department of Neurology, Kansas University School of Medicine, Kansas City, KS.; Department of Neurology, University of Missouri, Columbia, MO.
Corporate Authors: NeuroNEXT NN103 BeatMG Study Team
Source: Neurology [Neurology] 2022 Jan 25; Vol. 98 (4), pp. e376-e389. Date of Electronic Publication: 2022 Jan 25.
Publication Type: Journal Article
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1526-632X
DOI:10.1212/WNL.0000000000013121